AQ
AQSZF.US Aequus Pharmaceuticals Inc
- Market cap
- USD 39.8K
- P/E
- -
- P/B
- 32.78x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is AQSZF.US undervalued?
Graham numberThe Graham number of Aequus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aequus Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Aequus Pharmaceuticals Inc yet.
Aequus Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Full company profileAequus Pharmaceuticals Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aequus Pharmaceuticals Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 702K | 1.14M | 1.41M | 1.63M | 2.59M | 2.71M | 1.38M | 255K | 584K | 929K |
| Gross Profit | 0.00 | 702K | 1.14M | 1.41M | - | 2.59M | 2.69M | 1.28M | 144K | 332K | 501K |
| Operating Income | -5.06M | -4.86M | -3.91M | -2.81M | -2.22M | -526K | -1.37M | -2.50M | -2.82M | -2.13M | -356K |
| EBITDA | - | - | -3.73M | -2.62M | -2.38M | -315K | -1.23M | -2.87M | -2.68M | -1.79M | -275K |
| Net Income | -5.01M | -4.81M | -3.88M | -2.80M | -3.11M | -1.05M | -1.81M | -3.21M | -2.96M | -2.18M | -585K |
| EPS | - | - | -0.05 | -0.03 | -0.04 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 2.43M | 2.01M | 2.67M | 2.00M | 1.67M | 3.13M | 4.35M | 1.69M | 1.09M | 800K | 196K |
| Total Liabilities | 1.15M | 744K | 367K | 315K | 2.55M | 2.56M | 2.56M | 3.07M | 5.38M | 7.26M | 7.09M |
| Shareholders' Equity | 1.28M | 1.27M | 2.31M | 1.68M | -877K | 574K | 1.79M | -1.38M | -4.29M | -6.45M | -6.89M |
| Cash & Short-term Investments | 1.16M | 473K | 1.16M | 370K | 485K | 1.72M | 2.39M | 250K | 170K | 50.2K | 13.9K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.84M | -4.47M | -3.81M | -2.57M | -1.63M | -805K | -1.17M | -1.95M | -2.29M | -1.66M | -48.5K |
| Capital Expenditure | 5.21K | 48.9K | 48.9K | 11.4K | 2.68K | 12.3K | 4.12K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | -3.86M | -2.59M | -1.63M | -817K | -1.18M | -1.95M | -2.29M | -1.66M | -48.5K |
| Ratios | |||||||||||
| ROE | -390.1% | -380.2% | -168.4% | -166.7% | - | -182.1% | -101.1% | - | - | - | - |
| ROA | -206.3% | -239.4% | -145.3% | -140.4% | -185.7% | -33.3% | -41.6% | -189.8% | -272.9% | -272.1% | -298.1% |
| Net Profit Margin | - | -685.8% | -340.7% | -198.8% | -190.3% | -40.3% | -66.7% | -232.7% | -1,163.1% | -372.7% | -63.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aequus Pharmaceuticals Inc dividends
Aequus Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Aequus Pharmaceuticals Inc
- Insiders 14.68%
- Institutions 0.00%
- Public & others 85.32%
- Shares outstanding 133M
- Free float 112M
Aequus Pharmaceuticals Inc company profile
- Company name
- Aequus Pharmaceuticals Inc
- Ticker
- AQSZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 200 Granville Street, Vancouver, BC, Canada, V6C 1S4
- Phone
- 604 336 7906
- Website
- aequuspharma.ca
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Aequus Pharmaceuticals Inc management
1- Mr. Douglas Glen JanzenChairman, CEO & President · born 1969